Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer

被引：0

作者：

Lin, Binwei ^{[1
,2
]}

Fan, Jinjia ^{[3
]}

Liu, Fang ^{[3
]}

Wen, Yixue ^{[2
]}

Li, Jie ^{[2
]}

Gao, Feng ^{[2
]}

Zhang, Yu ^{[2
]}

Feng, Gang ^{[2
]}

Du, Xiaobo ^{[2
,4
]}

Chen, Wenzhi ^{[1
]}

机构：

[1] Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Med & Engn, Chongqing, Peoples R China

[2] Mianyang Cent Hosp, Dept Oncol, NHC Key Lab Nucl Technol Med Transformat, Mianyang, Peoples R China

[3] North Sichuan Med Coll, Dept Oncol, Affiliated Hosp, Nanchong, Peoples R China

[4] Univ Elect Sci & Technol, Mianyang Cent Hosp, Dept Oncol, Mianyang Cent Hosp,Sch Med,NHC Key Lab NuclearTech, Mianyang, Peoples R China

来源：

TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷

关键词：

neoadjuvant; HER2; pathologic complete response; pertuzumab; trastuzumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 2022 were included in this retrospective study. Docetaxel + trastuzumab + pertuzumab or docetaxel + carboplatin + trastuzumab + pertuzumab was selected as the neoadjuvant regimen. The primary endpoint was a complete pathological remission rate. Secondary endpoints were toxicity during neoadjuvant treatment, adjustment of the neoadjuvant therapy scheme, and adjuvant medication. Result: A total of 81 patients were included in this study (38 in the docetaxel + carboplatin + trastuzumab + pertuzumab treatment group and 43 in the docetaxel + trastuzumab + pertuzumab group). The complete pathological remission rates in the docetaxel + carboplatin + trastuzumab + pertuzumab and docetaxel + trastuzumab + pertuzumab groups were 44.7% (95% confidence interval: 30.2%-60.3%) and 51.2% (95% confidence interval: 36.8%-65.4%), respectively. The incidence of grade 3 or higher toxicity in the docetaxel + carboplatin + trastuzumab + pertuzumab group was significantly higher than that in the docetaxel + trastuzumab + pertuzumab group (68.4% vs 39.5%, P = .009). Neutropenia and asthenia were the most common grade 3 or higher toxicities. The incidence of neoadjuvant scheme adjustment was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (26.3% vs 7.0%, P = .039). The proportion of patients who received <6 cycles of neoadjuvant therapy was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (31.6% vs 4.7%, P = .004). Patients in the docetaxel + carboplatin + trastuzumab + pertuzumab group received higher doses of granulocyte-macrophage colony-stimulating factor. Conclusion: In the neoadjuvant treatment of HER2-positive breast cancer, the docetaxel + trastuzumab + pertuzumab regimen might be more tolerated than the docetaxel + carboplatin + trastuzumab + pertuzumab regimen and did not show a lower complete pathological remission rate. However, our findings require further validation through prospective studies.

引用

页数：8

共 30 条

[1] Does ponatinib cross the blood-brain barrier? [J].

Abid, Muhammad B. ;

De Mel, Sanjay .

BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (03) :497-498

[2] Acute lymphoblastic leukemia of the central nervous system: on the role of PBX1 [J].

Alsadeq, Ameera ;

Schewe, Denis M. .

HAEMATOLOGICA, 2017, 102 (04) :611-613

[3] Acute Lymphoblastic Leukemia, Version 2.2015 [J].

Alvarnas, Joseph C. ;

Brown, Patrick A. ;

Aoun, Patricia ;

Ballen, Karen Kuhn ;

Barta, Stefan K. ;

Borate, Uma ;

Boyer, Michael W. ;

Burke, Patrick W. ;

Cassaday, Ryan ;

Castro, Januario E. ;

Coccia, Peter F. ;

Coutre, Steven E. ;

Damon, Lloyd E. ;

DeAngelo, Daniel J. ;

Douer, Dan ;

Frankfurt, Olga ;

Greer, John P. ;

Johnson, Robert A. ;

Kantarjian, Hagop M. ;

Klisovic, Rebecca B. ;

Kupfer, Gary ;

Litzow, Mark ;

Liu, Arthur ;

Rao, Arati V. ;

Shah, Bijal ;

Uy, Geoffrey L. ;

Wang, Eunice S. ;

Zelenetz, Andrew D. ;

Gregory, Kristina ;

Smith, Courtney .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (10) :1240-1279

[4] Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report [J].

Cerveira, Nuno ;

Ferreira, Rosa Branca ;

Bizarro, Susana ;

Correia, Cecilia ;

Torres, Lurdes ;

Lisboa, Susana ;

Vieira, Joana ;

Santos, Rui ;

Campilho, Fernando ;

Vaz, Carlos Pinho ;

Leite, Luis ;

Teixeira, Manuel R. ;

Campos, Antonio .

BMC CANCER, 2018, 18

[5] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias [J].

Cortes, J. E. ;

Kim, D. -W. ;

Pinilla-Ibarz, J. ;

le Coutre, P. ;

Paquette, R. ;

Chuah, C. ;

Nicolini, F. E. ;

Apperley, J. F. ;

Khoury, H. J. ;

Talpaz, M. ;

DiPersio, J. ;

DeAngelo, D. J. ;

Abruzzese, E. ;

Rea, D. ;

Baccarani, M. ;

Mueller, M. C. ;

Gambacorti-Passerini, C. ;

Wong, S. ;

Lustgarten, S. ;

Rivera, V. M. ;

Clackson, T. ;

Turner, C. D. ;

Haluska, F. G. ;

Guilhot, F. ;

Deininger, M. W. ;

Hochhaus, A. ;

Hughes, T. ;

Goldman, J. M. ;

Shah, N. P. ;

Kantarjian, H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) :1783-1796

[6] Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Pinilla-Ibarz, Javier ;

le Coutre, Philipp D. ;

Paquette, Ronald ;

Chuah, Charles ;

Nicolini, Franck E. ;

Apperley, Jane F. ;

Khoury, H. Jean ;

Talpaz, Moshe ;

DeAngelo, Daniel J. ;

Abruzzese, Elisabetta ;

Rea, Delphine ;

Baccarani, Michele ;

Mueller, Martin C. ;

Gambacorti-Passerini, Carlo ;

Lustgarten, Stephanie ;

Rivera, Victor M. ;

Haluska, Frank G. ;

Guilhot, Francois ;

Deininger, Michael W. ;

Hochhaus, Andreas ;

Hughes, Timothy P. ;

Shah, Neil P. ;

Kantarjian, Hagop M. .

BLOOD, 2018, 132 (04) :393-404

[7] Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study [J].

Fielding, Adele K. ;

Richards, Susan M. ;

Chopra, Rajesh ;

Lazarus, Hillard M. ;

Litzow, Mark R. ;

Buck, Georgina ;

Durrant, I. Jill ;

Luger, Selina M. ;

Marks, David I. ;

Franklin, Ian M. ;

McMillan, Andrew K. ;

Tallman, Martin S. ;

Rowe, Jacob M. ;

Goldstone, Anthony H. .

BLOOD, 2007, 109 (03) :944-950

[8] UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia [J].

Fielding, Adele K. ;

Rowe, Jacob M. ;

Buck, Georgina ;

Foroni, Letizia ;

Gerrard, Gareth ;

Litzow, Mark R. ;

Lazarus, Hillard ;

Luger, Selina M. ;

Marks, David I. ;

McMillan, Andrew K. ;

Moorman, Anthony V. ;

Patel, Bella ;

Paietta, Elisabeth ;

Tallman, Martin S. ;

Goldstone, Anthony H. .

BLOOD, 2014, 123 (06) :843-850

[9] Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia [J].

Fielding, Adele K. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (01) :8-12

[10]

Gaur S, 2014, IN VIVO, V28, P1149

← 1 2 3 →